Results 171 to 180 of about 428,052 (282)

Evolutionary radiation of large‐bodied gorgonopsians from the lower Abrahamskraal formation of South Africa

The Anatomical Record, EarlyView.
Abstract The middle Permian represents a critical interval in therapsid evolution, when gorgonopsians emerged as some of the first specialized apex predators within terrestrial ecosystems. Despite their significance, the early diversification of Gorgonopsia in Gondwana remains poorly understood due to scarcity and fragmentary material.
Zanildo Macungo, Ricardo Araújo, Bruce S. Rubidge, Michael O. Day, Kathleen N. Dollman, Julien Benoit   +5 more
wiley   +1 more source

Visualization for Departures from Symmetry with the Power-Divergence-Type Measure in Square Contingency Tables. [PDF]

Psychometrika
Urasaki W, Nakagawa T, Tsuchida J, Tahata K.   +3 more
europepmc   +1 more source

Compensation Response to Hepatic Gluconeogenesis via β‐Hydroxybutyrylation of FBP1 and PCK1 in Dairy Cows

Animal Research and One Health, EarlyView.
(1) Kbhb modification of FBP1 and PCK1 is involved in regulation of the gluconeogenesis pathway. (2) Kbhb of FBP1 and PCK1 is catalyzed by p300 and removed by HDACs. (3) BHB induced an increase in the enzymatic activity of FBP1 and PCK1 through Kbhb modification at the K43 site of FBP1 and the K191 site of PCK1.
DingPing Feng, GuoYan Wang, YuanYuan Zhu, YiNing Zheng, JunHu Yao, Lei Chen, Lu Deng   +6 more
wiley   +1 more source

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab

Arthritis &Rheumatology, EarlyView.
Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial.
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators, Reem Al‐jayyousi, Yoshihiro Arimura, Jacqueline Andrews, Simon Bond, Marianna Nodale, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Michael Clarkson, Janak de Zoysa, Vimal Derebail, Tim Doulton, Tomomi Endo, Eri Muso, Tatsuo Tsukamoto, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz‐Singer, Yoshitomo Hamano, Lorraine Harper, Toshiko Ito‐Ihara, Rachel B. Jones, Nader Khalidi, Rainer Klocke, Curry L. Koening, Yoshinori Komagata, Hajime Kono, Shunya Uchida, Carol A. Langford, Peter Lanyon, Sarah Lawman, Raashid Luqmani, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Ken‐ei Sada, Richard Smith, Richard Watts, Robert Spiera, Antoine G. Sreih, Kazuo Suzuki, Vladamir Tesar, Augusto Vaglio, Giles Walters, Caroline Wroe   +62 more
wiley   +1 more source

Pharmacists expand access to contingency management in patients with substance use disorders. [PDF]

Ment Health Clin
Salsman M, Colvard M, Beam C, Frey T, Rothbauer K, Eatmon C.   +5 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Computational Modeling of Uncertainty and Volatility Beliefs in Escape-Avoidance Learning: Comparing Individuals with and Without Suicidal Ideation. [PDF]

J Pers Med
Blacutt M, O'Loughlin CM, Ammerman BA.
europepmc   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Risk‐aware safe reinforcement learning for control of stochastic linear systems

Asian Journal of Control, EarlyView.
Abstract This paper presents a risk‐aware safe reinforcement learning (RL) control design for stochastic discrete‐time linear systems. Rather than using a safety certifier to myopically intervene with the RL controller, a risk‐informed safe controller is also learned besides the RL controller, and the RL and safe controllers are combined together ...
Babak Esmaeili, Nariman Niknejad, Hamidreza Modares   +2 more
wiley   +1 more source

Risk-indexed artificial neural network for predicting duration and cost of irrigation canal-lining projects using survey-based calibration and python validation. [PDF]

Sci Rep
Taha B, Ibrahim AH, Soliman AA.
europepmc   +1 more source